Formononetin: A Pathway to Protect Neurons.
1The Second Clinical Medical School, Nanjing Medical University, Nanjing, China.
Frontiers in Integrative Neuroscience
|August 1, 2022
Summary
Formononetin, a phytoestrogen, shows significant neuroprotective effects against various neurological diseases. This research explores its potential as a novel therapeutic agent for central nervous system disorders.
Area of Science:
- Pharmacology
- Neuroscience
- Biochemistry
Background:
- Formononetin (FMN) is a phytoestrogen with diverse pharmacological properties including antioxidant, antihypertensive, antitumor, and anti-infective effects.
- FMN has demonstrated potential in preventing and treating neurological conditions such as traumatic brain injury (TBI), spinal cord injury (SCI), ischemic stroke, and Alzheimer's disease.
Purpose of the Study:
- To review and synthesize information on the neuroprotective signaling pathways of formononetin.
- To highlight FMN's potential as a therapeutic candidate for central nervous system (CNS) diseases.
Main Methods:
- Literature search focused on neuroprotective studies of formononetin.
- Analysis of signaling pathways involved in FMN's neuroprotective mechanisms.
Main Results:
- Formononetin exhibits significant neuroprotective functions.
- Identified key signaling pathways underlying FMN's therapeutic effects in neurological conditions.
Conclusions:
- Formononetin possesses considerable neuroprotective capabilities.
- FMN represents a promising novel candidate for developing drugs targeting the central nervous system.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
1.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
424
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
424
01:15Neurogenesis and Regeneration of Nervous Tissue
986
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
986